Biomarkers that indicate infection with Coccidioides
AssigneesArizona Board of Regents on behalf of Arizona State University, Mayo Foundation for Medical Education and Research
InventorsDouglas F. Lake, Thomas E. Grys, Natalie M. Mitchell
Life of this patent
Estimating the term…
Abstract
Detecting at least one biomarker indicative of coccidioidomycosis (Valley Fever) in a sample from a subject having or at risk for coccidioidomycosis (Valley Fever).
Claims10
A method for treating coccidioidomycosis (Valley Fever), the method comprising detecting a level of at least one biomarker in a sample from a subject, and administering a therapy to the subject, wherein the therapy is an antifungal therapy selected from the group consisting of fluconazole, itraconazole, amphotericin B, voriconazole, posaconazole, and isavuconazonium sulfate, and wherein the at least one biomarker is a protein from Coccidioides selected from the group consisting of:
- SEQ ID NO:2,
- SEQ ID NO:3,
- SEQ ID NO:4,
- SEQ ID NO:5,
- SEQ ID NO:6,
- SEQ ID NO:7,
- SEQ ID NO:8,
- SEQ ID NO:9,
- SEQ ID NO:10,
- SEQ ID NO:11,
- SEQ ID NO:12,
- SEQ ID NO:13, and
- SEQ ID NO:
- 14.
A method of identifying and treating a subject having coccidioidomycosis (Valley Fever), the method comprising:
- (1) performing laser capture microdissection on the lung tissue sample from a subject to detect a level of at least one biomarker protein in the sample by LC-MS, wherein the at least one biomarker is a protein from Coccidioides selected from the group consisting of:
- SEQ ID NO:2,
- SEQ ID NO:3,
- SEQ ID NO:4,
- SEQ ID NO:5,
- SEQ ID NO:6,
- SEQ ID NO:7,
- SEQ ID NO:8,
- SEQ ID NO:9,
- SEQ ID NO:10,
- SEQ ID NO:11,
- SEQ ID NO:12,
- SEQ ID NO:13, and
- SEQ ID NO:14;
- (2) comparing a level of at least one biomarker in the sample from the subject to a reference level,
- (3) identifying the subject having coccidioidomycosis (Valley Fever) with a level of the at least one biomarker in the sample that is above the reference level, and
- (4) administering a therapy to the subject having coccidioidomycosis (Valley Fever), wherein the therapy is an antifungal therapy selected from the group consisting of fluconazole, itraconazole, amphotericin B, voriconazole, posaconazole, and isavuconazonium sulfate.
Dependencies are inferred from the claim text.